37 results about "Tumor Antibodies" patented technology

The invention discloses a tumor-targeted CD38-pH low insertion peptide (pHLIP) fusion peptide. The fusion peptide is formed by connecting a pHLIP and a functional structure domain of CD38. The tumor microenvironment is acidic, under the acidic environment, the pHLIP can be inserted into a tumor cell membrane, by utilizing the properties of the pHLIP, the CD38 connected with the pHLIP is positionedon the surface of the tumor cell membrane in a targeted mode, through the technology, original tumor cells with tumor cell surfaces not expressing the CD38 can also be marked by the CD38, and thus antibody drugs aiming at the CD38 can exert the effects on the original tumor cells not expressing the CD38 as well. Through the research results, the indications of a specific tumor antibody drug are expanded, and clinical application prospects are good.

The invention relates to an antibody chip kit for diagnosis of various tumors. The kit includes an antibody chip, a tumor marker standard substance mixture, a biotin-labeled tumor marker detection antibody mixture, and a fluorescein Cy3-labeled streptavidin, wherein the antibody chip includes a substrate, 16 kinds of tumor marker specific antibodies fixed on the surface of the substrate, and two kinds of positive controls, and the tumor marker standard substance mixture is a freeze-dried mixture obtained by mixing 16 kinds of standard tumor marker standard substances together according to a certain amount. The kit can detect 16 clinical commonly used tumor markers, overcomes the defects of complicated operation, single detection index, low sensitivity and the like in the prior art, has the advantages of being cheap, convenient, sensitive, accurate, high in throughput, and less in amount of samples, and can be popularized and large-scaled in common laboratories.

The invention discloses a compound antibody containing interferon alpha / tumor antibody / oxidized graphene as well as a preparation method and applications. The compound antibody contains interferon alpha, the tumor antibody and oxidized graphene, wherein the interferon alpha, the tumor antibody and oxidized graphene are connected through non covalent bonds, and the tumor antibody is rituximab or trastuzumab. The compound antibody containing interferon alpha / tumor antibody / oxidized graphene can effectively and directly kill most tumor cells and damage the microenvironment protecting the tumor cells, and meanwhile, the interferon alpha stimulates an immune system, breaks the tumor tolerance, and promotes the specific cellular activation of tumors or the release of cell factors, so that the purposes of shrinking or eliminating tumors, preventing relapse and finally completely treating tumors are achieved.